GSK5784283 for Asthma
Trial Summary
What is the purpose of this trial?
This study is trying to find the right dose of a long-lasting medicine called GSK5784283 for people with asthma that remains uncontrolled even though they are using regular asthma treatments. GSK5784283 blocks the action of an inflammatory protein called TSLP that may be contributing to your asthma. The study will be conducted in two parts - Part A (dose finding phase) and Part B (extended dosing phase). Part A will assess the lung function, asthma control, participant safety and certain markers of asthma inflammation in the air you breath out and in your blood. Part B will assess the safety and long-term effects of the repeated or single doses of GSK5784283.
Eligibility Criteria
Adults aged 18-75 with uncontrolled asthma despite using regular treatments can join this study. They must have had asthma for at least 2 years, experienced an exacerbation within the last year, and be on medium or high-dose inhalers for 6 months. Women of childbearing potential must use effective contraception and provide negative pregnancy tests.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Dose Finding
Part A: Participants receive varying doses of GSK5784283 to assess lung function, asthma control, participant safety, and markers of asthma inflammation
Extended Dosing
Part B: Participants receive repeated or single doses of GSK5784283 to assess safety and long-term effects
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- GSK5784283
Find a Clinic Near You
Who Is Running the Clinical Trial?
GlaxoSmithKline
Lead Sponsor
Dame Emma Walmsley
GlaxoSmithKline
Chief Executive Officer since 2017
MA in Classics and Modern Languages from Oxford University
Dr. Hal Barron
GlaxoSmithKline
Chief Medical Officer since 2018
MD from Harvard Medical School